CN119638704A - 活化素受体样激酶抑制剂的盐和晶体形式 - Google Patents

活化素受体样激酶抑制剂的盐和晶体形式 Download PDF

Info

Publication number
CN119638704A
CN119638704A CN202411831775.3A CN202411831775A CN119638704A CN 119638704 A CN119638704 A CN 119638704A CN 202411831775 A CN202411831775 A CN 202411831775A CN 119638704 A CN119638704 A CN 119638704A
Authority
CN
China
Prior art keywords
compound
salt
alk2
peaks
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411831775.3A
Other languages
English (en)
Chinese (zh)
Inventor
C·梅登多普
D·玛扎伊克
G·威尔基
J·D·韦特齐格
B·海因里奇
L·麦凯克恩
D·西格尔
H·奥梅
S·C·约翰斯顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cable Chart Pharmaceutical Co
Original Assignee
Cable Chart Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cable Chart Pharmaceutical Co filed Critical Cable Chart Pharmaceutical Co
Publication of CN119638704A publication Critical patent/CN119638704A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202411831775.3A 2019-08-13 2020-08-12 活化素受体样激酶抑制剂的盐和晶体形式 Pending CN119638704A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962885977P 2019-08-13 2019-08-13
US62/885,977 2019-08-13
CN202080057092.0A CN114222745B (zh) 2019-08-13 2020-08-12 活化素受体样激酶抑制剂的盐和晶体形式
PCT/US2020/045847 WO2021030386A1 (en) 2019-08-13 2020-08-12 Salt and crystal forms of an activin receptor-like kinase inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080057092.0A Division CN114222745B (zh) 2019-08-13 2020-08-12 活化素受体样激酶抑制剂的盐和晶体形式

Publications (1)

Publication Number Publication Date
CN119638704A true CN119638704A (zh) 2025-03-18

Family

ID=72193669

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411831775.3A Pending CN119638704A (zh) 2019-08-13 2020-08-12 活化素受体样激酶抑制剂的盐和晶体形式
CN202080057092.0A Active CN114222745B (zh) 2019-08-13 2020-08-12 活化素受体样激酶抑制剂的盐和晶体形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080057092.0A Active CN114222745B (zh) 2019-08-13 2020-08-12 活化素受体样激酶抑制剂的盐和晶体形式

Country Status (14)

Country Link
US (1) US20220281879A1 (https=)
EP (1) EP4013757A1 (https=)
JP (2) JP7775186B2 (https=)
KR (1) KR20220052955A (https=)
CN (2) CN119638704A (https=)
BR (1) BR112022002597A2 (https=)
CA (1) CA3146701A1 (https=)
CO (1) CO2022001450A2 (https=)
IL (1) IL290482A (https=)
JO (1) JOP20220014A1 (https=)
MX (2) MX2022001741A (https=)
TW (1) TWI870440B (https=)
UA (1) UA130650C2 (https=)
WO (1) WO2021030386A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311889B (zh) * 2016-04-15 2021-11-16 缆图药品公司 激活素受体样激酶抑制剂
EP3870181B1 (en) 2018-10-26 2024-08-14 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311889B (zh) * 2016-04-15 2021-11-16 缆图药品公司 激活素受体样激酶抑制剂
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol

Also Published As

Publication number Publication date
JP2022544272A (ja) 2022-10-17
CN114222745A (zh) 2022-03-22
BR112022002597A2 (pt) 2022-07-05
CN114222745B (zh) 2025-03-25
CA3146701A1 (en) 2021-02-18
WO2021030386A1 (en) 2021-02-18
CO2022001450A2 (es) 2022-05-31
AU2020328534A1 (en) 2022-03-17
JP2025148406A (ja) 2025-10-07
EP4013757A1 (en) 2022-06-22
IL290482A (en) 2022-04-01
KR20220052955A (ko) 2022-04-28
TWI870440B (zh) 2025-01-21
JOP20220014A1 (ar) 2023-01-30
MX2024014312A (es) 2024-12-06
TW202120509A (zh) 2021-06-01
UA130650C2 (uk) 2026-04-08
JP7775186B2 (ja) 2025-11-25
US20220281879A1 (en) 2022-09-08
MX2022001741A (es) 2022-03-11

Similar Documents

Publication Publication Date Title
CN114222745B (zh) 活化素受体样激酶抑制剂的盐和晶体形式
US8415363B2 (en) Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
US7612077B2 (en) Crystalline forms of the anti-cancer compound ZD1839
WO2024027825A1 (zh) 一种cdk抑制剂及其磷酸盐的多晶型
US20140200232A1 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
EP3430004B1 (en) Solid state forms of nilotinib salts
WO2023138681A1 (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
TW202545917A (zh) Ｎ－［（１ｓ，２ｅ）－１－環丙基－３－（甲磺醯基）丙－２－烯－１－基］－２－（１，１－二氟乙基）－４－苯氧基嘧啶－５－甲醯胺的新固體形式
EP4438600A1 (en) Compound used as kinase inhibitor and use thereof
HK40069001A (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
US12559472B2 (en) Salts of a compound and the crystalline forms thereof
AU2020328534B2 (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
HK40117473A (zh) 活化素受体样激酶抑制剂的盐和晶体形式
HK40069001B (zh) 活化素受体样激酶抑制剂的盐和晶体形式
US20100179162A1 (en) Crystal forms of 4-[6-methoxy-7(3-piperidin-1-yl-propoxy) quinazoline-4yl) piperazine-1-carboxylic acid (4-isopropoxyphenyl)-amide
WO2016081538A1 (en) Solid state forms of ceritinib and salts thereof
HK40126640A (zh) 喹唑啉erbb抑制剂的药物形式
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
TW202448439A (zh) （Ｅ）－１－（（１０Ｓ）－４－（（４－（［１，２，４］三唑并［１，５－ａ］吡啶－７－基氧基）－２－氟－５－甲基苯基）胺基）－７，８，１０，１１－四氫－９Ｈ－６，１０－甲橋嘧啶并［４＇，５＇：５，６］吡啶并［３，２－ｂ］［１，４，７］噁二氮雜環壬烯－９－基）－４－（二甲基胺基）丁－２－烯－１－酮之多晶形式
TWI443096B (zh) ３－（５－（４－（３－氟丙基）哌嗪－１－基）苯並咪唑－２－基）－１－氮雜薁－２－酮之單水合晶型及其製備方法與藥學組成物
JP2023524622A (ja) ６－クロロ－７－（４－（４－クロロベンジル）ピペラジン－１－イル）－２－（１，３－ジメチル－１Ｈ－ピラゾール－４－イル）－３Ｈ－イミダゾ［４，５－ｂ］ピリジンの塩及び多形体
CN120344508A (zh) 苯并恶嗪酮类化合物的结晶及其制备

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40117473

Country of ref document: HK